Skip to content
Precision for Medicine
Contact
recrutement de patients-2

Stratégies de recrutement des patients

Trouver les bons patients pour votre essai peut s'avérer difficile, en particulier lorsque les populations concernées sont peu nombreuses, comme c'est le cas pour les essais sur les maladies rares.
L'approche holistique de Precision en matière de recrutement de patients s'appuie sur notre portée mondiale, notre vaste réseau de chercheurs spécialisés dans les maladies et les groupes de défense des patients pour élaborer une stratégie visant à faire correspondre le patient à votre essai clinique en fonction des critères de votre étude. Pour les thérapies ciblées, nous utilisons un dépistage basé sur les biomarqueurs pour trouver les patients susceptibles de répondre à votre thérapie, en agissant rapidement et en garantissant la qualité des données grâce à nos services de laboratoire spécialisés en interne.

Des stratégies intelligentes de recrutement de patients

Notre réseau s'étend sur toute la planète, tout comme vos patients.

patient_rec_img

Établir des relations avec les communautés et les spécialistes

Les relations avec les groupes de défense des patients et les médias sociaux permettent d'atteindre les communautés concernées.

Par ailleurs, nos relations établies avec des leaders d'opinion et des sites de recherche clinique dans le monde entier nous permettent d'accéder à un large éventail de populations de patients.

Étude de cas : recrutement d'une étude mondiale d'histoire naturelle : Comment trouver 200 patients rares

Un commanditaire a choisi Precision pour gérer une étude mondiale sur l'histoire naturelle d'une maladie rénale rare liée au chromosome X. Cette étude avait été recommandée par la FDA en raison du nombre extrêmement limité de données publiées sur cette maladie rare. L'étude avait été recommandée par la FDA en raison du nombre extrêmement limité de données publiées sur cette maladie rare. L'objectif était de caractériser la fonction rénale et le déclin des patients atteints de la maladie avant d'entamer une étude clinique de phase 2/3. L'étude, qui sera menée aux États-Unis, au Canada, en Australie et en Europe, suivra plus de 200 patients pendant environ deux ans.

Le recrutement était de loin le plus grand défi de l'étude, combinant une faible prévalence de la maladie et une population cible primaire - les jeunes hommes - avec des engagements de vie tels que l'école et le travail qui laissaient peu de temps pour participer à un essai qui n'offrait aucun avantage thérapeutique pour les participants et qui nécessiterait de se rendre dans une clinique tous les 3 à 6 mois.

Télécharger maintenant

Lisez les dernières informations sur le blog de Precision

Découvrez des analyses d'experts et élargissez votre compréhension grâce aux aperçus de Precision sur la recherche actuelle, les études de cas et les tendances.

Découvrez notre blog
Read: Case Study: Delivering an Early-Phase Autoimmune Trial Across Regions Case Study: Delivering an Early-Phase Autoimmune Trial Across Regions

Clinical Trials - Early Phase Research - Autoimmune

Case Study: Delivering an Early-Phase Autoimmune Trial Across Regions

|
    has third author: false, (SizeLimitingPyMap: {main={hs_id=214928090133, hs_child_table_id=0, hs_updated_at=1781285625399, hs_published_at=1781630742683, description=Deborah Spencer is a Senior Director of Project Management at Precision for Medicine with over 25 years of experience in clinical research. She specialises in leading global clinical trials across multiple phases, with deep expertise in complex study delivery. Deborah provides strategic oversight of programmes, leads high-performing teams, and partners closely with sponsors to ensure successful execution and regulatory readiness., avatar=Image{width=1200,height=1200,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Deborah%20Spencer.jpg',altText='Deborah Spencer',fileId=214838919278}, lastname=Spencer, hs_initial_published_at=1781285742914, hs_created_by_user_id=26433386, hs_created_at=1781285562019, hs_is_edited=false, hs_deleted_at=0, name=Deborah, job=Senior Director, Project Management, slug=deborah-spencer, hs_updated_by_user_id=26433386}, second={hs_id=214928170660, hs_child_table_id=0, hs_updated_at=1781285676367, hs_published_at=1781630742683, description=Anthea Gates is a Project Director with approximately 30 years of drug development and medical device industry expertise across all phases, over a variety of indications including breast, lung cancer, solid tumors and lymphoma, cutaneous T-cell lymphoma, malignant melanoma, squamous cell carcinoma, rare haematologic disease, autoimmune rheumatology, osteoarthritis, ocular burns, liver cirrhosis, myopia and pre-eclampsia. Committed to delivering quality and passionate about building positive relationships with clients and study teams to promote cohesive business practices and ensure the successful management of projects from start to finish. Anthea holds a proven track record in effective leadership of cross-functional teams across programs of studies, to the accomplishment of operational excellence., avatar=Image{width=372,height=546,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/profile.jpg',altText='profile',fileId=214846873938}, lastname=Gates, hs_initial_published_at=1781285742914, hs_created_by_user_id=26433386, hs_created_at=1781285639221, hs_is_edited=false, hs_deleted_at=0, name=Anthea, job=Project Director, slug=anthea-gates, hs_updated_by_user_id=26433386}, third={hs_id=214928090141, hs_child_table_id=0, hs_updated_at=1781285738567, hs_published_at=1781630742683, description=Claire Delaville is a Senior Project Manager at Precision for Medicine. She brings 18 years of experience across preclinical and clinical research, including more than a decade leading Phase I to IV studies in oncology, rare diseases, and immunology, with direct experience in first-in-human and multicenter oncology trials. Claire is responsible for maintaining study quality through inspection readiness, corrective action planning, and proactive risk mitigation. She also oversees study budgets and vendor performance to support coordinated delivery across functions, drawing on a scientific foundation that includes a PhD in Neurosciences and Neuropharmacology. Based in Paris, France, Claire aligns scientific insight with operational execution to support successful trial outcomes., avatar=Image{width=1200,height=1200,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Claire%20Delaville.jpg',altText='Claire Delaville',fileId=214838927033}, lastname=Delaville, hs_initial_published_at=1781285742914, hs_created_by_user_id=26433386, hs_created_at=1781285678112, hs_is_edited=false, hs_deleted_at=0, name=Claire, job=Senior Project Manager, slug=claire-delaville, hs_updated_by_user_id=26433386}})
  • Deborah S. avatar Anthea G. avatar Claire D. avatar

  • Deborah S.

    Anthea G.

    Claire D.
Découvrir
Read: Early‑Phase Autoimmune Drug Development: Trial Design, Biomarkers and Statistical Strategies Early‑Phase Autoimmune Drug Development: Trial Design, Biomarkers and Statistical Strategies

Clinical Trials

Early‑Phase Autoimmune Drug Development: Trial Design, Biomarkers and Statistical Strategies

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=213698206365, hs_child_table_id=0, hs_updated_at=1780680681226, hs_published_at=1781630742683, description=Rui F. Duarte‑Lopes is a senior biostatistics leader with over 31 years of international experience across biopharmaceutical, biotechnology, and CRO sectors. He provides strategic statistical oversight, ensuring rigorous, high‑quality, and decision‑focused delivery aligned with sponsor and regulatory expectations. He has more than 12 years of CRO experience supporting Phase I–IV clinical trials and has held roles including Lead Statistician, Project Lead, and Senior Manager. His therapeutic experience includes oncology and autoimmune diseases, notably lupus erythematosus, Crohn's disease and rheumatoid arthritis. Specializing in oncology over the past six years, Rui focuses on advanced solid tumors and early‑phase studies, contributing to study design, interim analyses, and data‑driven decision frameworks., avatar=Image{width=1200,height=1200,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Rui%20F%20Duarte-Lopes.jpg',altText='Rui F Duarte-Lopes',fileId=213695319705}, lastname=Duarte-Lopes, hs_initial_published_at=1779886328878, hs_created_by_user_id=26433386, hs_created_at=1779886165792, hs_is_edited=false, hs_deleted_at=0, name=Rui F, job=Senior Manager, Biostatistics, slug=rui-f-duarte-lopes, hs_updated_by_user_id=26433386}, second={}, third={}})
  • Rui F Duarte-Lopes avatar

    Rui F Duarte-Lopes
Découvrir
Read: Case Study: Advancing IHC Assays from RUO to Clinical Trials and CDx Case Study: Advancing IHC Assays from RUO to Clinical Trials and CDx

Assays - Oncology

Case Study: Advancing IHC Assays from RUO to Clinical Trials and CDx

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778874, hs_child_table_id=0, hs_updated_at=1765824406763, hs_published_at=1781630742683, description=Kennon Daniels is a scientific and regulatory in vitro diagnostic authority, specializing in the development of US regulatory strategies and FDA marketing submissions for IVD assays and instruments. Her expertise spans all aspects of product development, analytical and clinical trial protocol designs, Q-Submissions, IDEs, de novos, 510(k)s, and pre-market approval platforms., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Kennon%20Daniels.webp',altText='Kennon Daniels',fileId=165893120790}, linkedin=https://www.linkedin.com/in/kennon-daniels-ph-d-84a90b6, hs_name=, hs_path=, lastname=Daniels, PhD, hs_initial_published_at=1775839468505, hs_created_at=1709645745105, hs_is_edited=false, hs_deleted_at=0, name=Kennon, position=Vice President, IVD Regulatory Consulting, job=, slug=kennon-daniels, email=, hs_updated_by_user_id=26433386}, second={hs_id=164426546714, hs_child_table_id=0, hs_updated_at=1778171432595, hs_published_at=1781630742683, description=Angélique Heckmann, PhD is a people‑driven leader who combines scientific expertise and business acumen with a strong foundation in human values. With a background in therapeutic drug development and an MBA‑shaped strategic mindset, she focuses on building meaningful, long‑term relationships with teams, partners, and clients. By bridging science and strategy, she supports informed decision‑making, fosters collaboration, and helps translate innovation into real‑world impact—always guided by a shared purpose: advancing solutions that ultimately improve patients’ lives, avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/angelique-1.png',altText='angelique-1',fileId=194126030110}, lastname=Heckmann, PhD, hs_initial_published_at=1713174153602, hs_created_by_user_id=62155952, hs_created_at=1713172107894, hs_is_edited=false, hs_deleted_at=0, name=Angelique, job=Regional Vice President, Translational Business Solutions, slug=angelique-heckmann, hs_updated_by_user_id=26433386}, third={}})
  • Kennon D. avatar

    Kennon D.
  • Angelique H. avatar

    Angelique H.
Découvrir
Loading...